Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test
Supporting Files
-
5-2024
-
Available in CDC Stacks on 2024-05-01T00:00:00Z
File Language:
English
Details
-
Alternative Title:Infect Control Hosp Epidemiol
-
Personal Author:Guh, Alice Y.
;
Fridkin, Scott
;
Goodenough, Dana
;
Winston, Lisa G.
;
Johnston, Helen
;
Basiliere, Elizabeth
;
Olson, Danyel
;
Wilson, Christopher D.
;
Watkins, Jasmine J.
;
Korhonen, Lauren
;
Gerding, Dale N.
-
Description:Objective: ; Patients tested for Clostridioides difficile infection (CDI) using a 2-step algorithm with a nucleic acid amplification test (NAAT) followed by toxin assay are not reported to the National Healthcare Safety Network as a laboratory-identified CDI event if they are NAAT positive (+)/toxin negative (−). We compared NAAT+/toxin− and NAAT+/toxin+ patients and identified factors associated with CDI treatment among NAAT+/toxin− patients. ; Design: ; Retrospective observational study. ; Setting: ; The study was conducted across 36 laboratories at 5 Emerging Infections Program sites. ; Patients: ; We defined a CDI case as a positive test detected by this 2-step algorithm during 2018–2020 in a patient aged ≥1 year with no positive test in the previous 8 weeks. ; Methods: ; We used multivariable logistic regression to compare CDI-related complications and recurrence between NAAT+/toxin− and NAAT+/toxin+ cases. We used a mixed-effects logistic model to identify factors associated with treatment in NAAT+/toxin− cases. ; Results: ; Of 1,801 cases, 1,252 were NAAT+/toxin−, and 549 were NAAT+/toxin+. CDI treatment was given to 866 (71.5%) of 1,212 NAAT+/toxin− cases versus 510 (95.9%) of 532 NAAT+/toxin+ cases (P < .0001). NAAT+/toxin− status was protective for recurrence (adjusted odds ratio aOR, 0.65; 95% CI, 0.55–0.77) but not CDI-related complications (aOR, 1.05; 95% CI, 0.87–1.28). Among NAAT+/toxin− cases, white blood cell count ≥15,000/μL (aOR, 1.87; 95% CI, 1.28–2.74), ≥3 unformed stools for ≥1 day (aOR, 1.90; 95% CI, 1.40–2.59), and diagnosis by a laboratory that provided no or neutral interpretive comments (aOR, 3.23; 95% CI, 2.23–4.68) were predictors of CDI treatment. ; Conclusion: ; Use of this 2-step algorithm likely results in underreporting of some NAAT+/toxin− cases with clinically relevant CDI. Disease severity and laboratory interpretive comments influence treatment decisions for NAAT+/toxin− cases.
-
Subjects:
-
Source:Infect Control Hosp Epidemiol. 45(5):590-598
-
Pubmed ID:38268440
-
Pubmed Central ID:PMC11027077
-
Document Type:
-
Funding:
-
Volume:45
-
Issue:5
-
Download URL:
-
File Type:
-
Collection(s):
-
Main Document Checksum:urn:sha256:716c2d07209dc18711286d1496356cacc062a0790e52b3f9982b8b6a55091dc6
Supporting Files
File Language:
English
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings, journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
CDC Public Access